IP Verse

Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment

Patent No. EP3337467 (titled "Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment") was filed by Ipsen Biopharm on Aug 19, 2016. The application was issued on Dec 9, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SANDOZSep 9, 2021LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3337467

IPSEN BIOPHARM
Application Number
EP16757498A
Filing Date
Aug 19, 2016
Status
Revoked
Aug 11, 2023
Publication Date
Dec 9, 2020
External Links
Slate, Register , Google Patents